Clobazam in Subjects With Lennox-Gastaut Syndrome

Completed · Phase 2

Conditions studied: Epilepsy, Epilepsy, Generalized, Seizures

In brief

The purpose of this study is to evaluate the safety and efficacy of clobazam as adjunctive therapy in the treatment of seizures which lead to drop attacks (drop seizures) in subjects 2 to 30 years of age with Lennox-Gastaut Syndrome (LGS). Subjects will be enrolled at approximately 10 investigational sites in the U.S. for up to 15 weeks. Subjects will be randomly assigned to either a low dose or a high dose. The study will include a baseline period, a titration period and a maintenance period. After the maintenance period, subjects will either continue into an open-label extension study or enter the taper period with a final visit 1 week after the last dose.

Key facts

Study ID
NCT00162981
Run by
Lundbeck LLC
People needed
68
Starts
2005-10-01
Expected to finish
2006-10-01
Last updated by the study team
2012-02-09

Who can join

Age: 2 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.